• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 7, Issue 9
  3. Authors

Online ISSN: 2515-8260

Volume7, Issue9

The Efficacy Of Intralesional Bleomycin In The Treatment Of Recalcitrant Warts: An Open Therapeutic Trial In Iraq

    Ahmed Yahya Abbas Mustafa Hazim Ahmed Hiba Hikmat Maqdasi

European Journal of Molecular & Clinical Medicine, 2020, Volume 7, Issue 9, Pages 720-728

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background:
Aesthetically, warts affect on face and hands duo to great discomfort to the patient. The common treatment methods cause pigmentary changes and scarring. Moreover, recurrence of infection. Because bleomycin is considered an anti-tumor agent, this project is considered a pioneering study in Iraq to evaluate the efficacy of bleomycin intralesional in treating intractable warts.
Patient and Methods:
A total of 23 patients with (104) rebellious warts were treated with intralesional bleomycin. The response to treatment was followed after 2 weeks, 1 month and 3 months. The follow-up method was calculated by a special recording system (no response = 0), (response = 1) and (complete recovery = 2).
Results:
Results showed at 2 weeks follow up (13.1%) of the palmoplantar, (19.4%) of the periungual and (25%) of the other sites warts improved to score 1. After 1 month the score 1 response for palmoplantar, periungual and other sites warts were (39.2%), (41.9%) and (25%) respectively, while the score 2 response for palmoplantar, periungual and other sites warts were (30.4%), (32.3%) and (75%) respectively. After three month, reaction in periungual and other sites warts is 100%, whereas in palmoplantar warts were 94.2% with a total response rate of 96.1 % according to the scoring system.
Conclusion:
Our findings suggest that Bleomycin is significantly effective in the medication for insurgent warts. It's safe and free of side effects apart from minimal local pain with no recurrence rate of warts after bleomycin treatment.
Keywords:
    bleomycin Warts Palmoplantar Periungual Recalcitrant warts
  • PDF (731 K)
  • XML
(2020). The Efficacy Of Intralesional Bleomycin In The Treatment Of Recalcitrant Warts: An Open Therapeutic Trial In Iraq. European Journal of Molecular & Clinical Medicine, 7(9), 720-728.
Ahmed Yahya Abbas; Mustafa Hazim Ahmed; Hiba Hikmat Maqdasi. "The Efficacy Of Intralesional Bleomycin In The Treatment Of Recalcitrant Warts: An Open Therapeutic Trial In Iraq". European Journal of Molecular & Clinical Medicine, 7, 9, 2020, 720-728.
(2020). 'The Efficacy Of Intralesional Bleomycin In The Treatment Of Recalcitrant Warts: An Open Therapeutic Trial In Iraq', European Journal of Molecular & Clinical Medicine, 7(9), pp. 720-728.
The Efficacy Of Intralesional Bleomycin In The Treatment Of Recalcitrant Warts: An Open Therapeutic Trial In Iraq. European Journal of Molecular & Clinical Medicine, 2020; 7(9): 720-728.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 342
  • PDF Download: 360
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus